Drug intelligence / Profile preview

AD-221A + AD-221B

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-221A and AD-221B are investigational small molecule drugs developed by Addpharma, Inc. for the treatment of dyslipidemia and primary hypercholesterolemia. The combination of these two agents has been studied in clinical trials to evaluate their safety, pharmacokinetics, and efficacy compared to a single agent (AD-221) or coadministration as separate components. The exact mechanism of action is not fully detailed in available public sources, but they are likely involved in lipid metabolism modulation[1][8].

Other names: Atorvastatin/Ezetimibe FDCAD-221A + AD-221B

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on AD-221A + AD-221B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-221A + AD-221B.

Explore the full profile